Oncolytics Biotech (ONCY) - Reverse Split Alert

Price: $17.00 (post-split, 4/1/26)Market Cap: ~$30MSplit: 1-for-20 reverse split effective 3/31/26

What Happened

Oncolytics executed a 1-for-20 reverse stock split effective yesterday. Stock was trading sub-dollar pre-split. This is a Nasdaq compliance move, not a catalyst. Nothing changed fundamentally. Same company, same market cap, just fewer shares at a higher price.

Why It Matters

Reverse splits on sub-dollar biotechs are survival moves. It buys time on the listing but historically these setups don't end well. The company needed to get above $1.00 to avoid delisting and this was the only way to get there.

The Pipeline

Pelareorep is an intravenously delivered oncolytic reovirus immunotherapy. Phase 2 BRACELET-1 data in HR+/HER2- metastatic breast cancer showed an OS benefit (17.4 months vs 12.6 months) when added to paclitaxel + avelumab. GOBLET trial in pancreatic cancer ongoing. Partnered with Adlai Nortye for Greater China rights.

The science isn't dead. The OS data in breast cancer is real. But a $30M market cap post-reverse-split with cash concerns tells you the market isn't buying the story right now.

M&A Score: 35 | Growth Score: 25 | Tag: Pass

Too small, too distressed, reverse split screams desperation. The breast cancer OS data could attract a partner or buyer at the right price but no acquirer is stepping in while the company is fighting to keep its listing. If they stabilize the balance sheet and GOBLET reads out clean, revisit. Until then, pass.